Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis On Payer Contracts, Other Updates From BIO CEO & Investor Conference

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis' recent arrangements with Cigna and Aetna tying Entresto reimbursement to outcomes, new Gilead hires and a potential labeling change for Relypsa's Veltassa.

You may also be interested in...



Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.

Lilly Management Reorg Brings In Shaw To Oversee Bio-Medicines

Shaw is the former US President of rival Novartis and a rising figure in big pharma. She will take over the role previously held by Ricks, who became CEO Jan. 1. Conterno will assume President USA role.

Q3 Headwinds For Pharma Could Dampen A Continued Rally

COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel